Evidence map›Paper›PMID 42719253›Full record

ArticleRSC pharmaceutics2026

Phosphatidylserine-based liposomes encapsulating DMX-5804 protect against doxorubicin-induced cardiotoxicity.

Jessica Tetterton-Kellner, Audreanna Miserendino, Imran Tariq, Brian C Jensen, Juliane Nguyen

Abstract read
In one paragraph

Article in RSC pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Jessica Tetterton-KellnerDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill 4205 Marsico Hall 125 Mason Farm Rd Chapel Hill NC 27514 USA julianen@email.unc.edu.
Audreanna MiserendinoDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill 4205 Marsico Hall 125 Mason Farm Rd Chapel Hill NC 27514 USA julianen@email.unc.edu.
Imran TariqDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill 4205 Marsico Hall 125 Mason Farm Rd Chapel Hill NC 27514 USA julianen@email.unc.edu.
Brian C JensenMcAllister Heart Institute, University of North Carolina Chapel Hill NC 27599 USA.
Juliane NguyenDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill 4205 Marsico Hall 125 Mason Farm Rd Chapel Hill NC 27514 USA julianen@email.unc.edu.ORCID https://orcid.org/0000-0002-8578-7396

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Defining the role of mitochondrial injury in MEK inhibitor cardiotoxicityR01HL165294 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Brian C Jensen · 2023 to 2026
$2.1M
Engineering a cross-linked cellular network for cardiac repairR01HL161456 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NGUYEN, JULIANE · 2022 to 2025
$1.9M
Enhancement Training for the Next Generation of Translational Ph.D. ScientistsT32GM122741 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WOLBERG, ALISA S., YEH, JEN JEN · 2018 to 2022
$898k
Preclinical Vevo-F2 ultrasound imaging system for Small Animal Imaging core facilityS10OD034328 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI YUAN, HONG · 2023 to 2023
$491k
NCI NIH HHS P30 CA016086NHLBI NIH HHS R01 HL161456NHLBI NIH HHS R01 HL165294NIGMS NIH HHS T32 GM122741NIH HHS S10 OD034328
6 · The paper itself

Abstract

Anthracycline induced cardiotoxicity is a significant problem for oncologists and cancer patients. The leading cause of non-cancer death in cancer patients and survivors is heart failure, which is frequently attributed to the exposure to chemotherapeutics like anthracyclines. The most notorious of these chemotherapeutics is doxorubicin, which causes cardiac contractile dysfunction, which in some cases is irreversible. In this study, we report the development of NanoDMX, a phosphatidylserine-containing liposomal formulation of DMX5804, a small molecule inhibitor of MAP4K4, and demonstrate that its administration prevents doxorubicin-induced left ventricular dysfunction in mice. Additionally, we demonstrate that DMX-5804 protects cardiomyocytes

Identifiers

PMID42719253
PMCPMC13555785

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.